MXPA05006663A - Agentes del receptor linfotoxina beta en combinacion con agentes quimioterapeuticos. - Google Patents

Agentes del receptor linfotoxina beta en combinacion con agentes quimioterapeuticos.

Info

Publication number
MXPA05006663A
MXPA05006663A MXPA05006663A MXPA05006663A MXPA05006663A MX PA05006663 A MXPA05006663 A MX PA05006663A MX PA05006663 A MXPA05006663 A MX PA05006663A MX PA05006663 A MXPA05006663 A MX PA05006663A MX PA05006663 A MXPA05006663 A MX PA05006663A
Authority
MX
Mexico
Prior art keywords
combination
agents
beta receptor
lymphotoxin beta
lymphotoxin
Prior art date
Application number
MXPA05006663A
Other languages
English (en)
Inventor
Lepage Doreen
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of MXPA05006663A publication Critical patent/MXPA05006663A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a terapias de combinacion que incluyen una composicion que activa la senalizacion del receptor linfotoxina beta en combinacion con uno u otros mas agentes quimioterapeuticos, asi como tambien metodos terapeuticos y metodos de seleccion para identificar agentes que en combinacion con un agente agonista del receptor linfotoxina beta, tienen un efecto supra-aditivo en la inhibicion de tumor.
MXPA05006663A 2002-12-20 2003-12-22 Agentes del receptor linfotoxina beta en combinacion con agentes quimioterapeuticos. MXPA05006663A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43518502P 2002-12-20 2002-12-20
PCT/US2003/041243 WO2004058183A2 (en) 2002-12-20 2003-12-22 Lymphotoxin beta receptor agents in combination with chemotherapeutic agents

Publications (1)

Publication Number Publication Date
MXPA05006663A true MXPA05006663A (es) 2005-09-30

Family

ID=32682180

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05006663A MXPA05006663A (es) 2002-12-20 2003-12-22 Agentes del receptor linfotoxina beta en combinacion con agentes quimioterapeuticos.

Country Status (16)

Country Link
US (1) US20060134102A1 (es)
EP (1) EP1585547A4 (es)
JP (1) JP2006513225A (es)
KR (1) KR20050094819A (es)
CN (1) CN1753692A (es)
AU (1) AU2003303339A1 (es)
BR (1) BR0317573A (es)
CA (1) CA2509495A1 (es)
EA (1) EA200501019A1 (es)
IS (1) IS7900A (es)
MX (1) MXPA05006663A (es)
NO (1) NO20053529L (es)
PL (1) PL377611A1 (es)
RS (1) RS20050481A (es)
WO (1) WO2004058183A2 (es)
ZA (1) ZA200505543B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
JP2004532608A (ja) * 2000-10-13 2004-10-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド ヒト化抗ＬＴ−β−Ｒ抗体
EP1539235A2 (en) * 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
EP1539793A4 (en) * 2002-07-01 2006-02-01 HUMANIZED ANTIBODIES AGAINST THE RECEPTOR OF LYMPHOTOXIN BETA
AU2003299984A1 (en) * 2002-12-20 2004-07-22 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
US20050163782A1 (en) * 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
AU2005227322A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
PT1866339E (pt) 2005-03-25 2013-09-03 Gitr Inc Moléculas de ligação a gitr e suas utilizações
WO2006125632A2 (en) * 2005-05-24 2006-11-30 Rechtsanwalt Dr. Martin Prager Als Insolvenzverwalter Über Das Vermögen Der Xantos Biomedicine Ag, Pluta Rechtsanwalts Gmbh Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy
JP2009539999A (ja) * 2006-06-15 2009-11-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド 第２の薬剤との組み合わせにおいてリンホトキシンベータ受容体結合分子を使用する複合療法
TWI414531B (zh) 2006-10-12 2013-11-11 Genentech Inc 淋巴毒素α之抗體
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
US8067375B2 (en) * 2006-10-20 2011-11-29 Biogen Idec Ma Inc. Treatment of demyelinating disorders with soluble lymphotoxin-β-receptor
JP5932217B2 (ja) * 2007-07-12 2016-06-08 ジーアイティーアール， インコーポレイテッド Ｇｉｔｒ結合分子を使用する併用療法
SG11201802794PA (en) * 2015-10-06 2018-05-30 Univ Minnesota Therapeutic compounds and methods
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
US20210253723A1 (en) * 2018-06-15 2021-08-19 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
KR102232659B1 (ko) * 2018-07-16 2021-03-26 전북대학교 산학협력단 항원전달용 폴리펩타이드, 이를 포함하는 Fc-융합 단백질 및 이의 용도
JP2023506750A (ja) * 2019-12-11 2023-02-20 シラグ・ゲーエムベーハー・インターナショナル Ｌｔｂｒ及びｅｄｂ結合ドメインを含む多重特異性結合分子並びにその使用
CN117327174A (zh) * 2022-06-24 2024-01-02 广东菲鹏制药股份有限公司 抗新型冠状病毒人源化多价结合蛋白及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1996022788A1 (en) * 1995-01-26 1996-08-01 Biogen, Inc. LYMPHOTOXIN-α/β COMPLEXES AND ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
EE05213B1 (et) * 1996-10-25 2009-10-15 Biogen, Incorporated Lmfotoksiin- β retseptori (LT- β-R) blokeeriva agensi kasutamine ja LT- β-R-i blokeerivat agensit ning CD40L-i blokeerivat agensit sisaldav farmatseutiline kompositsioon
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
JP2004532608A (ja) * 2000-10-13 2004-10-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド ヒト化抗ＬＴ−β−Ｒ抗体
US7361343B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
EP1539793A4 (en) * 2002-07-01 2006-02-01 HUMANIZED ANTIBODIES AGAINST THE RECEPTOR OF LYMPHOTOXIN BETA
AU2003299984A1 (en) * 2002-12-20 2004-07-22 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
AU2005227322A1 (en) * 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof

Also Published As

Publication number Publication date
EP1585547A4 (en) 2006-10-25
KR20050094819A (ko) 2005-09-28
IS7900A (is) 2005-06-20
WO2004058183A3 (en) 2004-12-09
AU2003303339A1 (en) 2004-07-22
EA200501019A1 (ru) 2006-06-30
JP2006513225A (ja) 2006-04-20
BR0317573A (pt) 2005-11-22
NO20053529L (no) 2005-09-20
WO2004058183A2 (en) 2004-07-15
NO20053529D0 (no) 2005-07-19
ZA200505543B (en) 2006-12-27
EP1585547A2 (en) 2005-10-19
PL377611A1 (pl) 2006-02-06
CA2509495A1 (en) 2004-07-15
CN1753692A (zh) 2006-03-29
RS20050481A (en) 2007-08-03
US20060134102A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
RS20050481A (en) Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
PL377726A1 (pl) Sposoby i kompozycje do indukowania apoptozy komórek nowotworowych
SG147294A1 (en) Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy.
BG108214A (en) Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
WO2007146414A3 (en) Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents
MX2008008340A (es) Tratamiento de enfermedad de higado graso no alcoholica usando agentes reductores de colesterol y/o antagonista/agonista inverso de receptor de histamina 3.
GT200000053A (es) Moduladores del receptor glucocorticoide.
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
ZA200606844B (en) Use for interleukin-33 (IL33) and the IL-33 receptor complex
WO2006058236A3 (en) Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
UA89734C2 (en) ANTAGONISTS of muscarinic acetylcholine receptors
PL2251330T3 (pl) 4-hydroksybenzomorfany
EP1700120A4 (en) MARKER FOR OPTICAL NEUROMYELITIS
UA88440C2 (ru) ЛЕЧЕНИЕ ГЛОМЕРУЛОНЕФРИТА И ХРОНИЧЕСКОЙ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ ПРИ ПОМОЩИ ИНТЕРФЕРОНА-β
HK1143406A1 (en) Screening methods for cognitive enhancers
WO2004009616A3 (en) Ghrelin analogs
ZA200308147B (en) Use of neuronal sodium channel antagonists for the control of ectoparasites in homeothermic animals.
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
MY133625A (en) Peptide deformylase inhibitors
WO2002072021A3 (en) Agents and methods for the prevention of initial onset and recurrence of existing cancers
NZ506529A (en) Treatment of follicular lymphomas using inhibitors of the lymphotoxin (LT) pathway
WO2006057988A3 (en) Use of endothelin etb receptor agonists and eta receptor antagonists in tumor imaging
WO2003105891A3 (en) USE OF HEC1 ANTAGONISTS IN THE TREATMENT OF PROLIFERATIVE DISORDERS AND CANCERS
WO2008042436A3 (en) Biomarkers and assays for the treatment of cancer
DE69901805D1 (de) Pharmazeutische zusammensetzung mit mutiertem tyrosin 353 ezrin

Legal Events

Date Code Title Description
FA Abandonment or withdrawal